The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Obenshain Andrew since 2021.
This trader's CIK number is 1839697.
At the time of last reporting, Obenshain Andrew was the President and CEO of Bluebird Bio, Inc.. (stock ticker symbol BLUE).
Also see all insider trading activities at Bluebird Bio, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | BLUE | 0 | $0 | 1,147 | $5,537 | 0 | $0 |
| 2024 | BLUE | 0 | $0 | 37,630 | $20,359 | 0 | $0 |
| 2023 | BLUE | 0 | $0 | 17,736 | $62,516 | 0 | $0 |
| 2022 | BLUE | 0 | $0 | 30,793 | $177,363 | 0 | $0 |
| 2021 | BLUE | 0 | $0 | 2,218 | $49,590 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-03-03 | BLUE | Sale | 921 | 3.92 | 3,609 |
| 2025-02-03 | BLUE | Sale | 86 | 7.39 | 635 |
| 2025-01-06 | BLUE | Sale | 140 | 9.24 | 1,293 |
| 2024-12-10 | BLUE | Sale | 971 | .42 | 404 |
| 2024-09-30 | BLUE | Sale | 34,780 | .53 | 18,259 |
| 2024-02-05 | BLUE | Sale | 1,879 | .90 | 1,696 |
| 2023-11-03 | BLUE | Sale | 807 | 3.17 | 2,554 |
| 2023-08-10 | BLUE | Sale | 16,929 | 3.54 | 59,962 |
| 2022-11-04 | BLUE | Sale | 1,263 | 6.41 | 8,100 |
| 2022-08-04 | BLUE | Sale | 21,805 | 4.39 | 95,745 |
| 2022-01-10 | BLUE | Sale | 3,042 | 9.32 | 28,360 |
| 2022-01-11 | BLUE | Sale | 4,683 | 9.64 | 45,158 |
| 2021-12-07 | BLUE | Sale | 832 | 10.18 | 8,468 |
| 2021-06-04 | BLUE | Sale | 511 | 30.75 | 15,715 |
| 2021-05-03 | BLUE | Sale | 29 | 30.15 | 874 |
| 2021-04-05 | BLUE | Sale | 29 | 30.20 | 875 |
| 2021-03-02 | BLUE | Sale | 34 | 29.58 | 1,005 |
| 2021-02-17 | BLUE | Sale | 749 | 28.16 | 21,092 |
| 2021-02-02 | BLUE | Sale | 34 | 45.92 | 1,561 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Obenshain Andrew (President and CEO of Bluebird Bio, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.